vs

Side-by-side financial comparison of ANAVEX LIFE SCIENCES CORP. (AVXL) and Iveda Solutions, Inc. (IVDA). Click either name above to swap in a different company.

ANAVEX LIFE SCIENCES CORP. is the larger business by last-quarter revenue ($1.1M vs $626.0K, roughly 1.7× Iveda Solutions, Inc.). Iveda Solutions, Inc. runs the higher net margin — -258.6% vs -526.5%, a 267.9% gap on every dollar of revenue. On growth, ANAVEX LIFE SCIENCES CORP. posted the faster year-over-year revenue change (-22.6% vs -64.1%). Over the past eight quarters, Iveda Solutions, Inc.'s revenue compounded faster (34.4% CAGR vs -21.6%).

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical firm focused on developing novel small molecule therapeutics for neurodegenerative and neurodevelopmental disorders such as Alzheimer’s disease, Rett syndrome and Parkinson’s disease. It operates mainly across North America and European markets, targeting patients with high unmet medical needs.

Iveda Solutions, Inc. is a technology provider specializing in cloud-based AI video surveillance, IoT-enabled smart sensing, and integrated smart city solutions. It serves public sector, enterprise, and education clients across North America and Asia, with core offerings covering remote security monitoring, smart facility management, and real-time data analysis tools for public safety use cases.

AVXL vs IVDA — Head-to-Head

Bigger by revenue
AVXL
AVXL
1.7× larger
AVXL
$1.1M
$626.0K
IVDA
Growing faster (revenue YoY)
AVXL
AVXL
+41.5% gap
AVXL
-22.6%
-64.1%
IVDA
Higher net margin
IVDA
IVDA
267.9% more per $
IVDA
-258.6%
-526.5%
AVXL
Faster 2-yr revenue CAGR
IVDA
IVDA
Annualised
IVDA
34.4%
-21.6%
AVXL

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AVXL
AVXL
IVDA
IVDA
Revenue
$1.1M
$626.0K
Net Profit
$-5.7M
$-1.6M
Gross Margin
3.6%
Operating Margin
-628.5%
-262.7%
Net Margin
-526.5%
-258.6%
Revenue YoY
-22.6%
-64.1%
Net Profit YoY
53.1%
-7.1%
EPS (diluted)
$-0.06
$-0.33

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AVXL
AVXL
IVDA
IVDA
Q4 25
$1.1M
$626.0K
Q3 25
$999.0K
$1.7M
Q2 25
$1.1M
$1.5M
Q1 25
$1.2M
$1.5M
Q4 24
$1.4M
$1.7M
Q3 24
$1.8M
$2.4M
Q2 24
$1.8M
$1.5M
Q1 24
$1.8M
$346.8K
Net Profit
AVXL
AVXL
IVDA
IVDA
Q4 25
$-5.7M
$-1.6M
Q3 25
$-9.8M
$-221.3K
Q2 25
$-13.2M
$-564.2K
Q1 25
$-11.2M
$-793.7K
Q4 24
$-12.1M
$-1.5M
Q3 24
$-11.6M
$-581.4K
Q2 24
$-12.2M
$-599.0K
Q1 24
$-10.5M
$-1.3M
Gross Margin
AVXL
AVXL
IVDA
IVDA
Q4 25
3.6%
Q3 25
31.3%
Q2 25
29.1%
Q1 25
19.5%
Q4 24
11.9%
Q3 24
17.1%
Q2 24
32.7%
Q1 24
52.5%
Operating Margin
AVXL
AVXL
IVDA
IVDA
Q4 25
-628.5%
-262.7%
Q3 25
-1085.5%
-13.0%
Q2 25
-1345.0%
-34.8%
Q1 25
-1034.1%
-56.7%
Q4 24
-975.0%
-87.3%
Q3 24
-810.9%
-25.4%
Q2 24
-813.1%
-39.7%
Q1 24
-718.9%
-384.1%
Net Margin
AVXL
AVXL
IVDA
IVDA
Q4 25
-526.5%
-258.6%
Q3 25
-983.7%
-13.4%
Q2 25
-1231.9%
-36.9%
Q1 25
-925.3%
-53.8%
Q4 24
-868.8%
-86.7%
Q3 24
-660.2%
-24.2%
Q2 24
-680.1%
-39.0%
Q1 24
-600.6%
-371.9%
EPS (diluted)
AVXL
AVXL
IVDA
IVDA
Q4 25
$-0.06
$-0.33
Q3 25
$-0.11
$-0.07
Q2 25
$-0.16
$-0.20
Q1 25
$-0.13
$-0.28
Q4 24
$-0.14
$-0.60
Q3 24
$-0.14
$-0.27
Q2 24
$-0.14
$-0.30
Q1 24
$-0.13
$-0.64

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AVXL
AVXL
IVDA
IVDA
Cash + ST InvestmentsLiquidity on hand
$131.7M
$5.2M
Total DebtLower is stronger
$393.4K
Stockholders' EquityBook value
$126.6M
$4.8M
Total Assets
$133.0M
$6.4M
Debt / EquityLower = less leverage
0.08×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AVXL
AVXL
IVDA
IVDA
Q4 25
$131.7M
$5.2M
Q3 25
$102.6M
$3.3M
Q2 25
$101.2M
$1.6M
Q1 25
$115.8M
$2.5M
Q4 24
$120.8M
$2.6M
Q3 24
$132.2M
$3.6M
Q2 24
$138.8M
$2.9M
Q1 24
$139.4M
$3.9M
Total Debt
AVXL
AVXL
IVDA
IVDA
Q4 25
$393.4K
Q3 25
$306.4K
Q2 25
$365.3K
Q1 25
$340.8K
Q4 24
$376.2K
Q3 24
$545.9K
Q2 24
$564.0K
Q1 24
$480.0K
Stockholders' Equity
AVXL
AVXL
IVDA
IVDA
Q4 25
$126.6M
$4.8M
Q3 25
$94.9M
$3.8M
Q2 25
$91.0M
$1.5M
Q1 25
$99.8M
$1.7M
Q4 24
$110.9M
$2.5M
Q3 24
$120.3M
$4.1M
Q2 24
$129.8M
$2.8M
Q1 24
$135.0M
$3.3M
Total Assets
AVXL
AVXL
IVDA
IVDA
Q4 25
$133.0M
$6.4M
Q3 25
$103.8M
$5.8M
Q2 25
$102.4M
$4.4M
Q1 25
$117.1M
$4.5M
Q4 24
$124.0M
$5.2M
Q3 24
$135.6M
$9.1M
Q2 24
$141.5M
$6.8M
Q1 24
$144.5M
$6.6M
Debt / Equity
AVXL
AVXL
IVDA
IVDA
Q4 25
0.08×
Q3 25
0.08×
Q2 25
0.25×
Q1 25
0.20×
Q4 24
0.15×
Q3 24
0.13×
Q2 24
0.20×
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AVXL
AVXL
IVDA
IVDA
Operating Cash FlowLast quarter
$-7.2M
$-252.4K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AVXL
AVXL
IVDA
IVDA
Q4 25
$-7.2M
$-252.4K
Q3 25
$-8.6M
$-317.0K
Q2 25
$-12.5M
$-1.3M
Q1 25
$-5.9M
$-126.0K
Q4 24
$-12.1M
$-889.8K
Q3 24
$-6.7M
$-1.2M
Q2 24
$-5.2M
$-999.7K
Q1 24
$-11.7M
$-1.3M
Free Cash Flow
AVXL
AVXL
IVDA
IVDA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$-889.8K
Q3 24
$-1.5M
Q2 24
$-1.1M
Q1 24
$-1.5M
FCF Margin
AVXL
AVXL
IVDA
IVDA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-51.1%
Q3 24
-64.1%
Q2 24
-72.6%
Q1 24
-427.3%
Capex Intensity
AVXL
AVXL
IVDA
IVDA
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.0%
Q3 24
12.5%
Q2 24
7.5%
Q1 24
54.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons